Is Pharma Getting the Best out of Social Media? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Is Pharma Getting the Best out of Social Media?
With social media receiving increased focus as the pharma industry strives to make the most of new communication technologies, we speak with Cognizants Bhaskar Sambasivan to find out where pharma is when it comes to social media implementation and what more should be being done.



Many pharmaceutical companies use social media platforms as channels to distribute press releases and other company announcements. Is the industry exploiting the full potential of these public platforms?

Most Internet users actively use social media. Social networks have transformed the way we communicate and, more importantly, the platform they provide is the largest, most diverse and probably the most powerful medium of communication observed to date.

For the pharmaceutical industry, social networks offer a means to bridge the gap between companies and end users. Approximately 74% of pharmaceutical companies have adopted social media platforms (1) — a number that is significantly higher than the figures for financial services and retail companies. Despite the focus on and increased uptake of social media for businesses purposes, it is only one component in a communication strategy and not a complete solution. The level of adoption and maturity in successfully implementing social media and reaping business benefits is relatively low and inadequate because of various factors. For the pharmaceutical industry, one of the main hurdles is the stringent regulatory environment.

While many pharmaceutical companies do already use platforms like Twitter and Facebook for distributing press releases and other company announcements, these channels are also being used to promote awareness of health issues and diseases, managing corporate affairs, sharing corporate social responsibility initiatives and engaging with customers while providing them with efficient service in real-time.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here